INTRODUCTION
============

Reactive oxygen species (ROS) are forms of oxygen that are produced by the incomplete reduction of molecular oxygen \[[@B1]\]. ROS participate and regulate diverse downstream signaling pathways leading to specific cellular functions such as growth, metabolic rate, cell division, necrosis, apoptosis and the aging process \[[@B2],[@B3]\]. Although low levels of ROS play an important role in physiological functions, several studies have reported that high concentrations of ROS result in oxidative damage and induce cytotoxic effects in cells \[[@B4],[@B5]\]. Since hydrogen peroxide, one type of ROS, has remarkable membrane permeability \[[@B6]\], exposure of cells to exogenous hydrogen peroxide (H~2~O~2~) can induce detrimental effects \[[@B7]\]. From these processes, further oxidative stimulation will be propagated, damaging cellular molecules, and thus contributing to inflammation, aging, and cancer \[[@B8]-[@B10]\]. Increased mucosal concentrations of ROS have been implicated in the generation of gastrointestinal diseases, including acid-related peptic diseases and inflammatory disorders \[[@B11]\]. However, cell damage caused by free radicals in gastric or esophageal mucosa can be prevented by the administration of free radical scavengers \[[@B12],[@B13]\].

As seen in one study, an ischemic-like injury by oxygen-glucose deprivation activated 5-lipoxygenase mediated by oxidative stress through the p38 mitogen-activated protein kinase (MAPK) pathway in PC12 cells \[[@B14]\]. 5-Lipoxygenase (5-LOX) is a key enzyme within the arachidonic acid cascade \[[@B15]\]. 5-LOX catalyzes oxygenation of arachidonic acid, and produces 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and leukotrienes \[[@B16]\]. Leukotrienes (LT) play important roles in the inflammatory pathophysiologic process. LTB~4~, a subtype of LT, is a potent chemoattractant for neutrophils, eosinophils and monocytes including adherence of phagocytes to vessel walls, neutrophil degranulation as well as the release of superoxide anions \[[@B17]\]. Considering the potent pro-inflammatory properties of LTB~4~, the modulation of 5-LOX and LTB~4~ is of interest in the treatment of numerous diseases such as inflammatory disorders \[[@B18],[@B19]\].

Werz and Steinhilber \[[@B17]\] observed that p38 MAPK activation by cell stress is required for efficient leukotriene synthesis in B-lymphocytes. MAPK pathways are critical for converting diverse extracellular signals, including ROS, to biological responses. MAPKs modulate many cellular processes, such as gene induction, cell survival/apoptosis, as well as cellular stress and inflammatory responses \[[@B20]\]. ERK1/2 behave mainly as mitogen-activated proliferation/differentiation factors \[[@B21]\], whereas JNK and p38 MAP kinase are mainly stress-activated proteins related to apoptotic cell death \[[@B22]\]. Based on these evidences, in the present study, we tested the roles of 5-LOX and MAPKs in external H~2~O~2~ stimulation with esophageal epithelial cells.

On the other hand, flavonoids, which are secondary metabolites in plants, are considered relatively non-toxic bioactive substances and have diverse biological effects, such as anti-inflammatory, anti-oxidant, anti-allergic, hepatoprotective, anti-thrombotic, anti-viral, and anti-carcinogenic activities \[[@B23],[@B24]\]. Thus, these activities may explain the beneficial effects of flavonoid intake in different human pathologies, such as hypertension, inflammatory conditions, and even cancer \[[@B25]\]. In the present study, we used eupatilin (5,7-dihydroxy-3\'4\',6-trimethoxyflavone) being one of the pharmacologically active flavonoid components of Stillen to test the protective potential of flavonoids. Stillen (*Artemisia herba* extract) is a quality-controlled compound extracted from *Artemisiae argyi folium*, a traditional Korean herbal medicine for the treatment of abdominal tenderness, bloody diarrhea, and gynecological disorders. It shows muco-protective activity against noxious agents and exhibits favorable effects in experimental models of gastrointestinal disease such as gastritis, peptic ulcer, inflammatory bowel disease, and pancreatitis. Eupatilin has a potent antigastritic effect \[[@B26]\]. Eupatilin is reported to exert strong anti-inflammatory, and anti-oxidative activity as well as cytoprotective effects against experimentally induced gastrointestinal, hepatic, and pancreatic damage *in vivo* and *in vitro* \[[@B27]-[@B30]\].

Therefore, the purpose of this study is to investigate the anti-inflammatory potential and the cytoprotective mechanism of eupatilin on the H~2~O~2~-activated 5-LOX and LTB4 production in feline esophageal epithelial cells.

METHODS
=======

Materials
---------

Eupatilin was graciously provided by Dong-A Pharmaceutical Co., Ltd. (Yong-In, Korea) and dissolved in 0.1% dimethyl sulfoxide (DMSO). H~2~O~2~, bovine serum albumin (BSA), 4-(2-hydroxyethyle)-1-piperazine-N\'-2-ethane sulfonic acid (HEPES), leupeptin, aprotinin, β-mercaptoethanol, ethylene glycol-bis-(β-aminoethylether)-N,N,N\',N\'-tetraacetic acid (EGTA), ethylenediamine tetra acetic acid (EDTA), phenylmethyl-sulfonylfluoride (PMSF), thiazolyl blue tetrazolium bromide, Hank\'s Balanced Salt Solution-Modified (HBSS), NAC and NDGA were purchased from Sigma Chemical Co. (St. Louis, MO, USA); Fetal bovine serum (FBS), Antibiotic-Antimycotic (penicillin, streptomycin, amphotericin B), and trypsin-EDTA from Invitrogen (Grand Island, NY, USA); Dulbecco\'s modified Eagle\'s medium (DMEM), and phosphate-buffered saline (PBS) from Welgene Inc. (Daegu, South Korea); SB202190 and SP600125 from Calbiochem (San Diego, CA, USA); 5-LOX, phospho-SAPK/JNK, SAPK/JNK, phospho-p38 MAPK, and p38 MAPK antibodies from Cell Signaling Technology (Beverly, MA, USA); Actin antibody from Santa Cruz Biotechnology (Santa Cruz, CA, USA); goat anti-rabbit IgG-HRP, goat anti-mouse IgG-HRP, and rabbit anti-goat IgG-HRP from Zymed Laboratories Inc. (Eccles Avenue, CA, USA); Rainbow prestained molecular weight marker from Amersham (Arlington Heights, IL, USA); Enhanced Chemiluminescence (ECL) agents from PerkinElmer Life Sciences (Boston, MA, USA); Ammonium persulfate, N,N,N\',N\'-tetramethylethylene diamine (TEMED), nitrocellulose (NC) membrane, Tris/Glycine/SDS buffer, Tris/Glycine buffer, and 30% acrylamide/bis solution from BioRad (Richmond, CA, USA); RestoreTM Western Blot Stripping Buffer from Pierce (Rockford, IL, USA); LTB~4~ EIA kit from Cayman Chemical Company (Ann Arbor, MI, USA).

Preparation of feline esophageal epithelial tissue squares
----------------------------------------------------------

All animal experiments were approved by the Institutional Animal Care and Use Committee of Chung-Ang University, in accordance with the guide regarding the Care and Use of Laboratory Animals in Seoul, Korea. Adult cats of either sex weighing between 2.5 and 3.5 kg were anesthetized with Zoletil 50 (12.5 mg/0.25 ml/kg), which was composed of tiletamine and zolazepam, and euthanized with an overdose of 25% urethane (Aldrich, St. Louis, MO, USA). After the abdomen was opened with a midline incision, the esophagus was excised, cleaned and maintained in Krebs buffer composed of 116.6 mM NaCl, 21.9 mM NaHCO~3~, 1.2 mM NaH~2~PO~4~, 3.4 mM KCl, 2.5 mM CaCl~2~, 5.4 mM glucose and 1.2 mM MgCl~2~. The esophagus was opened along the lesser curvature. The location of the squamocolumnar junction was identified and the mucosa was then peeled off. The submucosal connective tissues were then removed by microspring scissors. The mucosa from esophagus was sliced into 0.5-mm-thick sections with a Stadie Riggs tissue slicer (Thomas Scientific Apparatus, Philadelphia, PA, USA). The last slices were cut into 2×2 mm tissue squares using scissors.

Cultures of feline esophageal epithelial cells
----------------------------------------------

The sliced tissue was placed into DMEM supplemented with 10% FBS containing 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 0.25 µg/ml amphotericin B and incubated in a humidified atmosphere of 5% CO~2~ and 95% air at 37℃ \[[@B31]\]. After 10 days, the medium was exchanged with fresh DMEM containing 10% FBS. After reaching confluence, the cells were detached using 1% trypsin in HBSS with bicarbonate. Afterwards, the cells were then counted, seeded at 2×10^5^ cells/ml on 100-mm culture dishes and maintained in DMEM containing 10% FBS. The medium was changed every 48 hours until the cells reached confluence. Experiments were performed on cells at passage 3 or 4.

Measurement of cell viability
-----------------------------

The cell viability was determined by the conventional 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) reduction assay using the method previously described \[[@B32]\]. Briefly, cells were made quiescent at confluence by incubation in serum-free DMEM for 24 hours to arrest cell growth and silence gene activity, followed by treatment with each indicated agent for the designated time periods. After incubation, the cells were rapidly washed twice with ice-cold PBS and incubated with MTT solution (final concentration, 5 mg/ml) for 4 hours at 37℃. Then, the supernatant was removed and the formazan crystals were dissolved with DMSO. Absorbance at 570 nm was measured with a microplate reader (Molecular Devices, Sunnyvale, CA, USA), and ECC Cell image were observed and acquired with Leica DM IL LED fluorescence microscopy (Leica Microsystems, Wetzlar, Germany).

Preparation of cell extracts
----------------------------

When the cells reached confluence, they were serum starved by incubation in serum-free DMEM for 24 hours. The cells were then stimulated with each compound for the indicated time periods or at the specified concentrations. After incubation, the cells were rapidly washed twice with ice-cold PBS and lysed with an ice-cold lysis buffer (20 mM Tris-HCl (pH 7.4), 0.5 mM EDTA, 0.5 mM EGTA, 1% (w/v) Triton X-100, 0.01% (w/v) SDS, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 1 mM PMSF, and 0.7 µg/ml β-mercaptoethanol) for 5 min. The lysates were scraped with a cell scraper and collected in Eppendorf tubes. They were then sonicated (6 seconds, 3×) and centrifuged for 10 min at 13,000 rpm at 4℃ to remove cellular debris; the supernatants were collected and stored at -70℃ for protein assay and Western blot analysis.

Western blot analysis
---------------------

Equal amounts of protein from each sample were subjected to electrophoresis on a 10% SDS-polyacrylamide gel and transferred to a NC membrane using the Power Pac 1,000 (Bio-Rad, Melville, NY, USA) power supply. To block any nonspecific binding, the NC membrane was incubated in 5% nonfat dry milk in PBS for 60 min followed by three rinses in milk-free PBS. The membranes were incubated overnight at 4℃ with primary antibodies raised against 5-LOX, phospho-SAPK/JNK, or phospho-p38 MAP kinase followed by three washes with PBS containing 0.05% Tween 20. This was followed by 60 min incubation in a horseradish peroxidase-conjugated secondary antibody. Immunoreactive proteins were detected with an ECL agent. Molecular masses were estimated by comparison with a prestained molecular mass marker. To confirm the uniformity of protein loading, the same blots were subsequently stripped with Western blot stripping buffer and reprobed with actin, SAPK/JNK, and p38 MAPK antibodies \[[@B33]\]. The results were analyzed by Quantity One analysis software (Bio-Rad Chemical Division, Richmond, CA, USA). The percentage of p38 MAPK, SAPK/JNK activation or the 5-LOX expression was calculated as the ratio of phosphorylated p38 MAPK to total p38 MAPK, phosphorylated SAPK/JNK to total SAPK/JNK or 5-LOX to Actin, respectively.

Measurements of LTB~4~ production from EECs
-------------------------------------------

Cells were pretreated with each indicated agent for the designated time periods. EECs were then stimulated with H~2~O~2~. Regarding experiments designed to measure the production of LTB~4~, the medium was collected, centrifuged, and stored at -70℃ until assayed \[[@B34]\]. The level of LTB~4~ released into the culture medium was quantified using a LTB~4~ EIA kit. Assays were then performed according to the manufacturer\'s instructions.

Statistics
----------

Differences among the groups were determined using Student\'s t-test. Data were expressed as the means±S.E.M. of 4\~6 experiments and differences between groups were considered significant at p\<0.05.

RESULTS
=======

The cytotoxic effect of external H~2~O~2~ in cultured EECs
----------------------------------------------------------

To investigate the cytotoxic effects concerning the external addition of H~2~O~2~, we performed MTT assays in cultured EECs. Cells were incubated with H~2~O~2~ at the indicated concentration for 24 hours, and then cell viability was measured using the MTT assay ([Fig. 1A](#F1){ref-type="fig"}). As a result, cell viability was significantly decreased by greater than 300 µM H~2~O~2~ in a concentration-dependent manner. Moreover, cell viability after exposure to 600 µM H~2~O~2~ was reduced to 40% of the control. In addition, morphologic observation of EECs treated with H~2~O~2~ was performed to identify the H~2~O~2~-induced morphologic change ([Fig. 1B](#F1){ref-type="fig"}). After H~2~O~2~ treatment, the number of cells was reduced and a high fraction of cells exhibited cytoplasmic condensation.

The identification of cytotoxicity of eupatilin
-----------------------------------------------

To study the cytotoxic effect of eupatilin, we employed the MTT assay in EECs ([Fig. 1C](#F1){ref-type="fig"}). We treated EECs with various concentrations of eupatilin for 24 hours. The cell viability did not show significant changes until 200 µM of eupatilin was used.

The protective effect of eupatilin on the H~2~O~2~-induced cell death
---------------------------------------------------------------------

To study the cytoprotective effect of eupatilin against H~2~O~2~-induced cell death, cells were pre-incubated with 25\~150 µM eupatilin for 12 hours and then exposed to 600 µM H~2~O~2~ for 24 hours ([Fig. 1D](#F1){ref-type="fig"}). H~2~O~2~ treatment alone significantly decreased cell viability to about 40%. However, when cells were pretreated with 25\~150 µM eupatilin for 12 hours, the cell viability was restored to roughly 65% of the control at a concentration of 150 µM. Morphologic observation of EECs treated with H~2~O~2~ in the absence or presence of eupatilin was also performed. ([Fig. 1E](#F1){ref-type="fig"}). H~2~O~2~ induced cytoplasmic condensation of EECs, whereas the morphology of cells incubated with H~2~O~2~ in the presence of 150 µM eupatilin was shown to maintain similar to control.

Effect of eupatilin on H~2~O~2~-induced 5-LOX expression
--------------------------------------------------------

To examine whether H~2~O~2~ causes 5-LOX expression in cultured EECs, the cells were exposed to H~2~O~2~ at the indicated concentrations, and then 5-LOX expression was measured by western blotting analysis. When the cells were treated with 100\~400 µM H~2~O~2~ for 24 hours, 5-LOX expression peaked at 300 µM H~2~O~2~ ([Fig. 2A](#F2){ref-type="fig"}). Next, to assess whether eupatilin affects H~2~O~2~-induced 5-LOX expression in EECs, western blotting analysis was performed ([Fig. 2B](#F2){ref-type="fig"}). After pre-treatment with the indicated concentration of eupatilin for 12 hours, EECs were further exposed to 300 µM H~2~O~2~ in the presence of eupatilin for 24 hours. Moreover, pretreatment with 100\~150 µM eupatilin significantly reduced the H~2~O~2~-induced 5-LOX protein expression. 5-Lox expression by H~2~O~2~ was reduced 10% by eupatillin.

Effect of eupatilin, MAPK inhibitors, ROS scavenger or LOX inhibitor on H2O2-induced 5-LOX expression and LTB4 production
-------------------------------------------------------------------------------------------------------------------------

Serum-starved EECs were treated with or without 150 µM eupatilin for 12 hours, 5 mM NAC, 30 µM SB202190 or 30 µM SP600125 for 1 hours prior to 300 µM H~2~O~2~ stimulation for 24 hours. As shown in [Fig. 3A](#F3){ref-type="fig"}, pretreatment of the cells with SB202190, SP600125 or NAC significantly reduced H~2~O~2~-induced the 5-LOX expression. These results indicated that p38 MAPK, JNK and ROS scavenging action may mediate the inhibitory effect of eupatilin on the 5-LOX expression by H~2~O~2~. In parallel experiments, the inhibitory effect of eupatilin on H~2~O~2~-induced LTB~4~ production was determined using LTB~4~ EIA kit ([Fig. 3B](#F3){ref-type="fig"}). [Fig. 3B](#F3){ref-type="fig"} showed that treatment of cultured EECs with H~2~O~2~ caused a significant increase in the production of LTB~4~. However, when EECs were treated with eupatilin, SB202190, SP600125, NAC or NDGA (a lipoxygenase inhibitor), the levels of LTB~4~ production was significantly reduced by all of them. Eupatilin and inhibitors reduced 10\~12 pg/ml of LTB~4~ production. These data were similar to the results of the 5-LOX expression by H~2~O~2~ with or without inhibitors.

Effect of H~2~O~2~ on activation of MAPKs
-----------------------------------------

To determine the effect of H~2~O~2~ on activation of MAPKs, the phosphorylation of p38 MAPK and JNK was investigated. The concentration-dependence of p38 MAPK and JNK phosphorylation was investigated by Western blot analysis ([Fig. 4](#F4){ref-type="fig"}). p38 MAPK and JNK phosphorylation levels were significantly increased by 300 µM H~2~O~2~. P38 MAPK expression after exposure to 300 µM H~2~O~2~, in [Fig. 4A](#F4){ref-type="fig"}, was increased to 40% of the control and JNK activation after exposure to 300 µM H~2~O~2~, in [Fig. 4B](#F4){ref-type="fig"}, was increased to 30% of the control.

Effect of eupatilin, MAPK inhibitors, and ROS scavenger on H~2~O~2~-induced p38 MAPK and JNK phosphorylation
------------------------------------------------------------------------------------------------------------

Serum-starved EECs were treated in the presence or absence of 150 µM eupatilin for 12 hr and with NAC, SB202190 or SP600125 for 1 hr prior to 300 µM H~2~O~2~ treatment for 24 hr. p38 MAPK and JNK phosphorylation levels in EECs were estimated by Western blot analysis ([Fig. 5](#F5){ref-type="fig"}). Pretreatment with eupatilin, NAC, SB202190, or SP600125 inhibited the expression of H~2~O~2~-induced p38 MAPK and JNK phosphorylation.

The group with H~2~O~2~ treatment as well as Eupatilin, in [Fig. 5A](#F5){ref-type="fig"}, decreased 21% when compared to that of the H~2~O~2~ treatment alone. The ROS scavengers presented similar effect to Eupatilin, and MAPK inhibitors showed further decrease down to 30%, similar to that of the non-treated group. In [Fig. 5B](#F5){ref-type="fig"}, the effect of drugs and reagents on P-JNK/T-JNK cell were shown. Eupatilin, MAPK inhibitors, and ROS scavenger treated groups showed diminishment as well.

DISCUSSION
==========

In this study, the addition of external H~2~O~2~ to esophageal epithelial cells exhibited significant cytotoxicity. The cell viability was decreased and the shapes of cells were remarkably altered. However, eupatilin enhanced the reduction of cell viability by H~2~O~2~. Previously, we identified that the cytoprotective properties of eupatilin could be attributed to the induction of the antioxidant protein heme oxygenase-1 (HO-1) in ileal smooth muscle cells or esophageal epithelial cells \[[@B30],[@B35]\]. We also confirmed that eupatilin induced HO-1 expression in esophageal epithelium of rats *in vivo* \[[@B35]\]. Cytoprotective roles for HO-1 have been demonstrated in many models, such as in hyperoxia-induced lung injury and reperfusion-induced injury of a transplanted liver \[[@B36],[@B37]\]. It has been known that a variety of phytochemicals in medicinal herbs and dietary plants exert potent antioxidative and anti-inflammatory action via induction of HO-1 \[[@B38],[@B39]\]. Eupatilin is also a flavonoid compound isolated from a traditional Korean herbal medicine, *Artemisiae argyi folium*. In the present study, although we did not test for the role of eupatilin-induced HO-1 in cell death by H~2~O~2~, we expect that the ability of eupatilin regarding HO-1 induction may be involved in cytoprotection against H~2~O~2~-induced cytotoxicity. In addition, the cytotoxicity of H~2~O~2~ could be associated with its ability to induce the expression of 5-LOX. As one study previously demonstrated, methyl jasmonate which is a plant stress hormone, induced apoptosis in human prostate carcinoma cells via 5-LOX dependent pathway \[[@B40]\]. In our study, co-treatment of eupatilin with H~2~O~2~ inhibited the increase of the H~2~O~2~-stimulated 5-LOX expression and LTB~4~ production. Therefore, it is possible that the cytoprotective effect of eupatilin could involve its ability to decrease the 5-LOX expression.

ROS act as second messengers to stimulate intracellular signaling pathways including MAPK \[[@B41]\]. Modulation of the MAPK signaling pathways by H~2~O~2~ is distinctive, depending on the cell type, concentration and duration of exposure. For example, exogenous H~2~O~2~ activates ERK and JNK but not p38 MAPK in human gastric epithelial cells \[[@B42]\], while endogenous H~2~O~2~ production by ethanol treatment in EECs activates ERK, but not JNK and p38 MAPK. As shown in our results, the H~2~O~2~-induced 5-LOX expression and LTB~4~ production were mediated by activation of p38 MAPK and JNK. Eupatilin inhibited H~2~O~2~-induced p38 MAPK and JNK activation. Considering the inhibitory effect of SB202190and SP600125on the 5-LOX expression, eupatilin may involve inhibition of the p38 MAPK and JNK pathways. In macrophages LTB4 or LTD4 have pro-proliferative effects through MAPK and phosphatidyl inositol 3-kinase pathways \[[@B43]\]. In addition, ERKs and p38 MAPK-regulated signaling can act stimulation of 5-LOX \[[@B44]\], and stress-induced nuclear export of 5-LOX is through activation of the p38 MAPK pathway \[[@B45]\]. Considering these observations, we suppose that MAPKs might participate in upstream or downstream of 5-LOX pathway as mediators.

The therapeutic approach and chemical design of anti-inflammatory agents has mainly targeted the development of selective cycloxygenase (COX) inhibitors. However, various leukotrienes, in particular LTB~4~, have emerged as new targets because of their contribution to the inflammatory process at the site of injury. For this reason, development of compounds that will inhibit COX and 5-LOX simultaneously could lead to enhanced anti-inflammatory effects and reduce undesirable side effects \[[@B46]\]. Eupatilin is already known as an effective COX inhibitor. For example, eupatilin remarkably inhibits LPS-induced expression of COX-2 in J774A.1 cells in a concentration-dependent manner \[[@B47]\]. In addition, eupatilin exhibits a down-regulatory effect on the COX-2 expression in carrageenan-induced inflammation within an air pouch on the backs of mice \[[@B48]\].

Considering the 5-LOX-inhibiting effect of eupatilin in the present study, eupatilin might act as a dual inhibitor with regards to COX and 5-LOX. Taken together, the present study provides evidence that eupatilin has a protective effect against H~2~O~2~-induced cell damage in cultured feline EEC. Eupatilin also inhibits the H~2~O~2~-induced 5-LOX expression and LTB~4~ production through the inactivation of p38 MAPK and JNK pathways.
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![Effect of H~2~O~2~ on the cell viability of feline EECs and Effect of eupatilin on the H~2~O~2~-induced cell viability. Serum-starved EECs were incubated with H~2~O~2~ for 24 hours at the indicated concentration. (A) The cell viability was estimated using MTT assay. (B) The morphologic changes of EECs were observed (magnification: 100×). (C) Serumstarved EECs were incubated in the presence of eupatilin alone for 12 hours at the indicated concentration. (D) the cells were incubated in the 600 µM H~2~O~2~ with or without eupatilin 12 hours before and during 24 hours, and then their survival was estimated using the MTT assay and the morphologic changes of cells were observed (E) (magnification: 100×). Data are expressed as Means±S.E of four experiments (^\*^; p\<0.05 vs. control, ^\*\*^; p\<0.01 vs. control, ^\#^; p\< 0.05 vs. H~2~O~2~ alone, ^\#\#^; p\<0.01 vs. H~2~O~2~ alone).](kjpp-16-313-g001){#F1}

![Effects of eupatilin on the H~2~O~2~-induced 5-LOX expression. (A) Serum-starved EECs were treated with H~2~O~2~ for 24 hours at each dose. (B) Serum-starved cells were preincubated in the presence of eupatilin for 12 hours at the indicated concentration and then stimulated with 300 µM H~2~O~2~ for 24 hours. 5-LOX expression was estimated by Western blot. Data are expressed as Means±S.E of three experiments (^\*^; p\<0.05 vs. control, ^\#^; p\<0.05 vs. H~2~O~2~ alone).](kjpp-16-313-g002){#F2}

![The effect of eupatilin, SB202190, SP600125 or NAC on the H~2~O~2~-induced 5-LOX expression and LTB~4~ production. Serum-starved EECs were preincubated in the presence of eupatilin (150 µM, 12 hours), SB202190 (30 µM, 1 hours), SP600125 (30 µM, 1 hours), or NAC (5 mM, 1 hours). The cells were then stimulated with H~2~O~2~ (300 µM, 24 hours). (A) The change level of 5-LOX expression was estimated by Western blot analysis. (B) The production level of LTB~4~ was estimated by LTB~4~EIA kit. Data are expressed as Means±S.E of three experiments (^\*^; p\<0.05 vs. control, ^\#^; p\<0.05, ^\#\#^; p\<0.01 vs. H~2~O~2~ alone).](kjpp-16-313-g003){#F3}

![p38 MAPK and JNK phosphorylation by H~2~O~2~. Serum-starved EECs were stimulated with H~2~O~2~ for 24 hr at each dose. (A) The change in the level of phosphorylated p38 MAPK was estimated by Western blot analysis. (B) The change of phosphorylated JNK level was estimated by Western blot analysis. Data are expressed as Means±S.E of three experiments (^\*^; p\<0.05 vs. control, ^\*\*^; p\<0.001 vs. control).](kjpp-16-313-g004){#F4}

![The effect of eupatilin, SB202190, SP600125, NAC on p38 MAPK (A) and (B) JNK phosphorylation in EECS. Serum-starved EECs were preincubated in the presence of eupatilin (150 µM, 12 hr), SB202190 (p38 MAPK inhibitor, 30 µM, 1 hr), SP600125 (JNK inhibitor, 30 µM, 1hr), or NAC (N-acetyl-L-cysteine, ROS scavenger, 5 mM, 1 hr). EECs were then stimulated with H~2~O~2~ (300 µM, 24 hr). The change of phosphorylated p38MAPK and JNK was estimated by Western blot analysis. Data are expressed as Means±S.E of three experiments (^\#^; p\<0.05 vs. control, ^\*^; p\<0.05 vs. H~2~O~2~ alone).](kjpp-16-313-g005){#F5}
